羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600285 羚锐制药

已收盘 01-08 15:00:00

{"stockData":{"symbol":"600285","market":"SH","secType":"STK","nameCN":"羚锐制药","latestPrice":20.98,"timestamp":1736319601000,"preClose":21.5,"halted":0,"volume":9188325,"delay":0,"changeRate":-0.0242,"floatShares":567000000,"shares":567000000,"eps":1.1917,"marketStatus":"已收盘","change":-0.52,"latestTime":"01-08 15:00:00","open":21.5,"high":21.67,"low":20.6,"amount":193000000,"amplitude":0.0498,"askPrice":20.98,"askSize":275,"bidPrice":20.97,"bidSize":565,"shortable":0,"etf":0,"ttmEps":1.1917,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736386200000},"marketStatusCode":5,"adr":0,"adjPreClose":21.5,"symbolType":"stock","openAndCloseTimeList":[[1736299800000,1736307000000],[1736312400000,1736319600000]],"highLimit":23.65,"lowLimit":19.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":567115486,"isCdr":false,"pbRate":4.11,"roa":"--","peRate":17.605102,"roe":"20.44%","epsLYR":1.012,"committee":-0.103691,"marketValue":11898000000,"turnoverRate":0.0162,"status":1,"floatMarketCap":11898000000},"requestUrl":"/m/hq/s/600285","defaultTab":"news","newsList":[{"id":"2501876744","title":"羚锐制药收盘下跌2.42%，滚动市盈率17.61倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2501876744","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501876744?lang=zh_cn&edition=full","pubTime":"2025-01-08 18:34","pubTimestamp":1736332493,"startTime":"0","endTime":"0","summary":"1月8日，羚锐制药今日收盘20.98元，下跌2.42%，滚动市盈率PE达到17.61倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均40.94倍，行业中值26.29倍，羚锐制药排名第28位。截至2024年三季报，共有46家机构持仓羚锐制药，其中基金41家、其他4家、社保1家，合计持股数22336.02万股，持股市值55.35亿元。河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/08183447262769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0077","BK0239","BK0070","600285","BK0188"],"gpt_icon":0},{"id":"2501227634","title":"羚锐制药125万股限制性股票激励计划授予完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2501227634","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501227634?lang=zh_cn&edition=full","pubTime":"2025-01-07 17:55","pubTimestamp":1736243725,"startTime":"0","endTime":"0","summary":"财中社1月7日电羚锐制药 发布关于股份性质变更暨2024年限制性股票激励计划授予的进展公告。根据公司2024年第一次临时股东大会的授权，董事会于2024年12月19日召开会议，决定以10.96元/股的价格向9名激励对象授予125万股限制性股票。激励对象已全部完成缴款，合计缴纳1370万元。2024年前三季度，羚锐制药实现收入27.59亿元，归母净利润5.74亿元。文章来源：财中社羚锐制药125万股限制性股票激励计划授予完成","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107180915a218a9d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250107180915a218a9d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0077","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2501021784","title":"羚锐制药01月06日主力资金流出407万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2501021784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501021784?lang=zh_cn&edition=full","pubTime":"2025-01-06 15:21","pubTimestamp":1736148116,"startTime":"0","endTime":"0","summary":"01月06日, 羚锐制药股价跌0.14%，报收21.51元，成交金额1.33亿元，换手率1.09%，振幅3.25%，量比0.94。羚锐制药今日主力资金净流出407万元，连续3日净流出，上一交易日主力净流出640万元，今日环比减少36.41%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为62.50%，平均跌幅为2.09%。该股近5个交易日下跌4.44%，主力资金累计净流出2335万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1.41亿元，其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106154134aba022d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250106154134aba022d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0188","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2500113036","title":"羚锐制药回复监管函：收购银谷制药将形成一定商誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2500113036","media":"新京报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500113036?lang=zh_cn&edition=full","pubTime":"2025-01-03 21:04","pubTimestamp":1735909457,"startTime":"0","endTime":"0","summary":"1月3日，羚锐制药回复上交所监管工作函，说明收购银谷制药一事的相关问题。2024年12月5日，羚锐制药宣布拟使用自有资金收购银谷制药100%股权，后者综合估值暂定不超过7.82亿元。同时，羚锐制药也提示，本次收购交割完成后，银谷制药将成为公司的控股子公司，在公司合并资产负债表中预计将形成一定金额的商誉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103210643a2145529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250103210643a2145529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","600285","BK0239","BK0070","BK0188"],"gpt_icon":0},{"id":"2500118848","title":"溢价收购银谷制药，“财大气粗”的膏药大王羚锐制药披露更多交易细节，却似有意避开风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2500118848","media":"市场资讯","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500118848?lang=zh_cn&edition=full","pubTime":"2025-01-03 20:25","pubTimestamp":1735907100,"startTime":"0","endTime":"0","summary":"　　宣布收购银谷制药约一个月后，羚锐制药昨日在监管工作函回复公告中披露了一些交易细节。最终，持续推进长达10个月的交易无疾而终。　　仅仅相隔4个月，银谷制药再觅得接盘方，羚锐制药要一次性购入银谷制药所有股份。这一交易招致上海证券交易所下发监管工作函，要求羚锐制药从交易标的、交易方案、交易价格三大方面进行补充披露和充分风险提示。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-01-03/doc-inectaaq8666544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0239","BK0188","600285","BK1574","BK0070","BK1191","01477"],"gpt_icon":0},{"id":"2500196097","title":"羚锐制药收盘上涨0.61%，滚动市盈率18.08倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2500196097","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500196097?lang=zh_cn&edition=full","pubTime":"2025-01-03 18:35","pubTimestamp":1735900544,"startTime":"0","endTime":"0","summary":"1月3日，羚锐制药今日收盘21.54元，上涨0.61%，滚动市盈率PE达到18.08倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均39.77倍，行业中值26.64倍，羚锐制药排名第30位。截至2024年三季报，共有46家机构持仓羚锐制药，其中基金41家、其他4家、社保1家，合计持股数22336.02万股，持股市值55.35亿元。河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318383495f7a71d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010318383495f7a71d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","BK0188","BK0077","BK0239","600285"],"gpt_icon":0},{"id":"2500576923","title":"羚锐制药参芪降糖胶囊拟中选集中带量采购项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2500576923","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500576923?lang=zh_cn&edition=full","pubTime":"2025-01-02 20:36","pubTimestamp":1735821360,"startTime":"0","endTime":"0","summary":"财中社1月2日电羚锐制药 发布关于公司产品拟中选全国中成药采购联盟集中带量采购的公告。公司参与了全国中成药采购联盟的投标工作，近日公布的拟中选结果显示，参芪降糖胶囊拟中选该采购项目。该产品的拟中选价格为25.01元/盒，适应症为Ⅱ型糖尿病，预计采购周期自中选结果执行之日起至2027年12月31日。2024年前三季度，羚锐制药实现收入27.59亿元，归母净利润5.74亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501022038159858dfc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501022038159858dfc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0188","BK0077","BK0070","BK0239"],"gpt_icon":0},{"id":"2500923575","title":"羚锐制药回复上交所监管工作函","url":"https://stock-news.laohu8.com/highlight/detail?id=2500923575","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500923575?lang=zh_cn&edition=full","pubTime":"2025-01-02 20:13","pubTimestamp":1735819980,"startTime":"0","endTime":"0","summary":"北京商报讯 1月2日晚间，羚锐制药发布关于对上交所监管工作函回复的公告。据了解，羚锐制药拟使用自有资金收购银谷制药100%股权。对此，上交所要求羚锐制药结合标的资产最新业绩情况、目前评估进展及可比交易案例，说明本次交易金额确定的依据及合理性等。本次交易评估定价是根据银谷制药目前生产经营状况，结合市场竞争等诸多因素，充分审慎测算的结果，评估定价具有合理性和可实现性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010220155895f67509&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010220155895f67509&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0077","600285","BK0070","BK0239"],"gpt_icon":0},{"id":"2500694592","title":"羚锐制药(600285.SH)：参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2500694592","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500694592?lang=zh_cn&edition=full","pubTime":"2025-01-02 18:10","pubTimestamp":1735812608,"startTime":"0","endTime":"0","summary":"智通财经APP讯，羚锐制药 发布公告，近日，公司参与全国中成药采购联盟集中带量采购的投标工作。本次拟中选产品参芪降糖胶囊为国家医保目录及国家基药目录产品。2023年参芪降糖胶囊销售额约为17480.55万元，占公司2023年度营业收入的5.28%。本次药品集中采购是全国中成药联合采购办公室组织的全国中成药集中带量采购，在执行上要求医疗机构优先使用本次药品集中采购中选药品，并确保完成约定采购量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600285","BK0188","BK0077","BK0070","BK0239"],"gpt_icon":0},{"id":"2500453119","title":"羚锐制药最新公告：公司产品参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2500453119","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500453119?lang=zh_cn&edition=full","pubTime":"2025-01-02 18:00","pubTimestamp":1735812016,"startTime":"0","endTime":"0","summary":"羚锐制药公告，公司产品参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购，拟中选价格为25.01元/盒，采购周期自中选结果执行之日起至2027年12月31日。参芪降糖胶囊为国家医保目录及国家基药目录产品，2023年销售额约为1.75亿元，占公司2023年度营业收入的5.28%。公司表示，本次拟中选将有利于进一步扩大产品销售，提高市场占有率，提升品牌影响力，对未来经营具有积极影响。但拟中选结果仍处于公示期间，采购合同签订等后续事项及对公司的影响尚具有不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010200026647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","BK0077","600285"],"gpt_icon":0},{"id":"2500394361","title":"【羚锐制药：参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购】羚锐制药公告，公司产品参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购。2023年该产品销售额约为1.75亿元，占公司2023年度营业收入的5.28%。2024年1-9月销售额约为1.66亿元，占公司2024年前三季度营业收入的6.01%。本次拟中选产品价格虽有一定程度下降，但将有利于公司扩大销售，提高市场占有率和品牌影响力。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500394361","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2500394361?lang=zh_cn&edition=full","pubTime":"2025-01-02 17:52","pubTimestamp":1735811573,"startTime":"0","endTime":"0","summary":"羚锐制药公告，公司产品参芪降糖胶囊拟中选全国中成药采购联盟集中带量采购。2023年该产品销售额约为1.75亿元，占公司2023年度营业收入的5.28%。2024年1-9月销售额约为1.66亿元，占公司2024年前三季度营业收入的6.01%。本次拟中选产品价格虽有一定程度下降，但将有利于公司扩大销售，提高市场占有率和品牌影响力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02175247045776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["600285"],"gpt_icon":0},{"id":"2495685573","title":"国金证券：给予羚锐制药买入评级，目标价位25.94元","url":"https://stock-news.laohu8.com/highlight/detail?id=2495685573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495685573?lang=zh_cn&edition=full","pubTime":"2024-12-31 08:28","pubTimestamp":1735604880,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维近期对羚锐制药进行研究并发布了研究报告《改革成效明显，中药贴膏龙头阔步向前》，本报告对羚锐制药给出买入评级，认为其目标价位为25.94元，当前股价为22.16元，预期上涨幅度为17.06%。我们给予公司25年19xPE，对应市值147.1亿元，对应目标价25.94元，首次覆盖给予公司“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024123100007980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285"],"gpt_icon":0},{"id":"2495839466","title":"医药袁维丨羚锐制药公司深度研究：改革成效明显，中药贴膏龙头阔步向前","url":"https://stock-news.laohu8.com/highlight/detail?id=2495839466","media":"国金证券研究所","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495839466?lang=zh_cn&edition=full","pubTime":"2024-12-31 08:18","pubTimestamp":1735604330,"startTime":"0","endTime":"0","summary":"我们仍看好未来公司继续降本增效，释放利润空间。潜在突破：2024年12月4日，公司发布公告，拟使用自有资金收购银谷制药100%的股权，对银谷制药综合估值暂定为不超过人民币78,212万元。银谷制药23年实现营收约2.15亿元，归母净利润约1396万元，扭亏为盈。我们认为，若交易达成，银谷制药的1类新药苯环喹溴铵鼻喷雾剂有望弥补公司鼻喷雾剂型产品的空白，同时增强公司院内销售推广能力；公司院外销售渠道亦有望为银谷制药产品放量赋能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231082326a20fab29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241231082326a20fab29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0077","BK0188","BK0239","BK0070","159938"],"gpt_icon":0},{"id":"2495510148","title":"羚锐制药收盘下跌1.55%，滚动市盈率18.60倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2495510148","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495510148?lang=zh_cn&edition=full","pubTime":"2024-12-30 19:05","pubTimestamp":1735556729,"startTime":"0","endTime":"0","summary":"12月30日，羚锐制药今日收盘22.16元，下跌1.55%，滚动市盈率PE达到18.60倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均41.83倍，行业中值27.30倍，羚锐制药排名第28位。截至2024年三季报，共有46家机构持仓羚锐制药，其中基金41家、其他4家、社保1家，合计持股数22336.02万股，持股市值55.35亿元。河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301907529854ec35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202412301907529854ec35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600285","BK0077","BK0188","BK0070"],"gpt_icon":0},{"id":"2495375871","title":"一周复盘 | 羚锐制药本周累计下跌1.57%，中药板块下跌3.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2495375871","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2495375871?lang=zh_cn&edition=full","pubTime":"2024-12-29 10:27","pubTimestamp":1735439265,"startTime":"0","endTime":"0","summary":"12月23日至12月27日本周上证指数上涨0.95%，中药板块下跌3.62%。羚锐制药本周累计下跌1.57%，周总成交额6.97亿元，截至本周收盘，羚锐制药股价为22.51元。截至目前，羚锐集团持有羚锐制药股份121817898股，占公司总股本的21.48%。2024年前三季度，羚锐制药实现收入27.59亿元，归母净利润5.74亿元。截至本公告披露日，羚锐集团及其一致行动人累计质押公司股份42994148股，占公司总股本的7.58%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/29102746919193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0070","BK0239","BK0077","600285"],"gpt_icon":0},{"id":"2494035641","title":"羚锐制药新提交“大器”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2494035641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494035641?lang=zh_cn&edition=full","pubTime":"2024-12-28 06:21","pubTimestamp":1735338105,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日河南羚锐制药股份有限公司新提交“大器”商标注册申请。商标申请详情如下：今年以来河南羚锐制药股份有限公司新申请注册商标6件，截止目前公司共持有注册商标539件，另有13件商标尚在注册申请中。数据来源：企查查以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122800006462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","600285","BK0070","BK0239"],"gpt_icon":0},{"id":"2494028821","title":"羚锐制药（600285）股东河南羚锐集团有限公司质押830万股，占总股本1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2494028821","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494028821?lang=zh_cn&edition=full","pubTime":"2024-12-25 21:23","pubTimestamp":1735133039,"startTime":"0","endTime":"0","summary":"证券之星消息，羚锐制药12月25日公开信息显示，股东河南羚锐集团有限公司向招商银行股份有限公司郑州分行合计质押830.0万股，占总股本1.46%。质押详情见下表：截止本公告日，股东河南羚锐集团有限公司已累计质押股份4299.41万股，占其持股总数的35.29%。羚锐制药主营业务：药品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122500036005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600285","BK0188","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2493701281","title":"羚锐制药收盘上涨1.40%，滚动市盈率18.86倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2493701281","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493701281?lang=zh_cn&edition=full","pubTime":"2024-12-24 18:50","pubTimestamp":1735037427,"startTime":"0","endTime":"0","summary":"12月24日，羚锐制药今日收盘22.48元，上涨1.40%，滚动市盈率PE达到18.86倍。从行业市盈率排名来看，公司所处的中药行业市盈率平均42.04倍，行业中值27.38倍，羚锐制药排名第29位。股东方面，截至2024年9月30日，羚锐制药股东户数30925户，较上次增加1621户，户均持股市值35.28万元，户均持股数量2.76万股。河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/24185046753891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0077","BK0070","BK0239","BK0188","600285"],"gpt_icon":0},{"id":"2493829557","title":"羚锐制药12月23日遭主力抛售2674万元 环比增加6936.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493829557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493829557?lang=zh_cn&edition=full","pubTime":"2024-12-23 15:20","pubTimestamp":1734938454,"startTime":"0","endTime":"0","summary":"12月23日, 羚锐制药股价跌3.06%，报收22.17元，成交金额2.14亿元，换手率1.69%，振幅3.94%，量比0.87。羚锐制药今日主力资金净流出2674万元，上一交易日主力净流出38万元，今日环比增加6936.84%。|12月23日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|卓翼科技|10.67%|#|小方制药|7.78%|#|威领股份|4.64%|#|蒙娜丽莎|4.32%|#|C博科测试|3.47%|#|爱婴室|3.26%|#|南凌科技|2.82%|#|威奥股份|2.71%|#|晶华微|2.61%|#|潍柴重机|2.53%|羚锐制药所在的中药Ⅱ行业，今日主力净流出4.07亿元，行业排名29/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223154300ab8d5313&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223154300ab8d5313&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600285","BK0239","BK0188","BK0077","BK0070"],"gpt_icon":0},{"id":"2492841644","title":"羚锐制药收盘上涨2.37%，滚动市盈率19.19倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2492841644","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492841644?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:05","pubTimestamp":1734692748,"startTime":"0","endTime":"0","summary":"12月20日，羚锐制药今日收盘22.87元，上涨2.37%，滚动市盈率PE达到19.19倍，创13天以来新低。从行业市盈率排名来看，公司所处的中药行业市盈率平均43.52倍，行业中值29.41倍，羚锐制药排名第29位。截至2024年三季报，共有46家机构持仓羚锐制药，其中基金41家、其他4家、社保1家，合计持股数22336.02万股，持股市值55.35亿元。河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220191051a1fd9bfe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220191051a1fd9bfe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0188","BK0070","BK0077","600285"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"河南省信阳市新县将军路666号","stockEarnings":[{"period":"1week","weight":-0.0532},{"period":"1month","weight":-0.0301},{"period":"3month","weight":-0.174},{"period":"6month","weight":-0.12},{"period":"1year","weight":0.2639},{"period":"ytd","weight":-0.0532}],"companyName":"河南羚锐制药股份有限公司","boardCode":"AI0027","perCapita":"18338股","boardName":"医药制造业","registeredCapital":"56711万元","compareEarnings":[{"period":"1week","weight":-0.0363},{"period":"1month","weight":-0.0507},{"period":"3month","weight":-0.0217},{"period":"6month","weight":0.0871},{"period":"1year","weight":0.1164},{"period":"ytd","weight":-0.0363}],"survey":"　　河南羚锐制药股份有限公司的主营业务为中成药制剂、化药制剂的研发、生产和销售。公司主要产品包括通络祛痛膏、壮骨麝香止痛膏、丹鹿通督片、培元通脑胶囊、参芪降糖胶囊、糠酸莫米松乳膏、小儿退热贴、咳宁胶囊、锐枢安芬太尼透皮贴剂等。公司先后获评“全国中药工业50强企业”“全国中药系统先进集体”“国家技术创新示范企业”等荣誉称号。","serverTime":1736368546727,"listedPrice":8.3,"stockholders":"30925人(较上一季度增加5.53%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"羚锐制药,600285,羚锐制药股票,羚锐制药股票老虎,羚锐制药股票老虎国际,羚锐制药行情,羚锐制药股票行情,羚锐制药股价,羚锐制药股市,羚锐制药股票价格,羚锐制药股票交易,羚锐制药股票购买,羚锐制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"羚锐制药(600285)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供羚锐制药(600285)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}